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Patients with glaucoma showed to have higher daytime sleepiness measured by Epworth sleepiness scale. In addition, this symptom
was associated with pupillary reflex and polysomnography parameters. These ipRGC functions might be impaired in patients with
glaucoma, leading to worse quality of life.
1. Introduction
The hypothalamic suprachiasmatic nucleus, the primary
circadian oscillator in humans, is the site for the master
circadian clock [1, 2]. Light phase shifts the endogenous
oscillator in the hypothalamic suprachiasmatic nucleus, syn-
chronizing it with the day-night cycle [1, 2]. Some years
ago, a study of human eyes culminated in the breakthrough
discovery of intrinsically photosensitive retinal ganglion cells
(ipRGCs), which constitute a subtype of retinal ganglion
cells (RGCs) that express melanopsin, a photopigment that
is most sensitive to short-wavelength blue light (480 nm)
[3, 4]. In addition to being intrinsically light-sensitive [3, 5–
7], ipRGCs are associated with circadian, neuroendocrine,
and neurobehavioral functions as well as having influence on
some image-forming functions [6–9].
Glaucoma, an optic neuropathy characterized by the
progressive loss of RGCs, is associated with morphological
changes in the optic nerve and the retinal nerve fiber layer
(RNFL) [10]. Several investigators have explored whether
light transmission to the hypothalamic suprachiasmatic
nucleus or the postillumination pupillary light response
(PLR) is compromised as a result of ipRGC damage in
glaucoma [11–14]. The activity of ipRGCs has been evaluated
in patients with glaucoma using either the light-induced
reduction of nocturnal pineal melatonin secretion or the PLR
test as a functional indicator of melanopsin-based photo-
transduction [12–14]. Most of these previous studies have
shown significant reductions in ipRGC function in affected
eyes compared with the eyes of healthy subjects [11–14]. In
addition, previous studies using the PLR test have demon-
strated significant correlations between decreased ipRGC
function and functional [11, 13] and structural [15] damage
in patients with glaucoma.
Few studies have tried to find an association between
abnormal ipRGC function and the severity of sleep disorders
in glaucoma patients [16, 17]. Wang et al. used the self-rated
Pittsburgh Sleep Quality Index (PSQI) to evaluate whether
glaucoma affects sleep quality [16]. These authors showed
that the prevalence of sleep disorders was higher among
patients with glaucoma than among healthy participants [16].
Although these studies indicate that patients with glaucoma
exhibit significantly altered sleep patterns that are also cor-
related with the PLR test, the relationships between objec-
tive polysomnographic measures and self-reported diurnal
symptoms (e.g., excessive daytime sleepiness) have yet to be
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established. Furthermore, daytime sleepiness has not been
associated with ipRGC functions such as PLR.
The degree of daytime sleepiness can be assessed using
the Epworth sleepiness scale (ESS), which can be helpful in
diagnosing sleep disorders [18].The ESS score has never been
determined in a glaucomatous population, nor has it been
associated with the objective polysomnography measures
that are considered as the gold-standard test for assessing
sleep disorders. The study uses the PLR (as a parameter for
ipRGCdysfunction) and correlated thesemeasurements with
ESS and polysomnography to evaluated correlations between
sleep disorder and ipRGC function.
2. Methods
Theprotocol for this cross-sectional study followed the tenets
of the Declaration of Helsinki and was approved by the
Institutional Review Board of the Federal University of Sa˜o
Paulo (CEP 262.470).Written informed consentwas obtained
from all subjects.
2.1. Study Sample. A total of 40 participants were recruited
from the Federal University of Sa˜o Paulo. Thirty of these
participants had primary open-angle glaucoma, and 10 others
were included for the control group. The inclusion and
exclusion criteria, as well as the ophthalmological assess-
ments, have been previously used and are described in
detail as follows [15, 17]. All subjects underwent a com-
plete ophthalmological examination, including a medical
history review, best-corrected visual acuity measurement,
slit-lamp biomicroscopy, gonioscopy, intraocular pressure
(IOP) measurement, dilated fundoscopic examination using
a 78-diopter (D) lens, refraction, and standard automated
perimetry (SAP) using the Swedish interactive threshold
algorithm (SITA Standard 24-2; Carl Zeiss Meditec, Inc.,
Dublin, CA, USA). Subjects were excluded if they were
younger than 40 years old or older than 80 years old;
had a best-corrected visual acuity worse than 0.2 logMAR
(logarithm of the minimum angle of resolution); had a pre-
vious history of ophthalmic surgery; had lens opacity greater
than 0.5 (cortical opacity, nuclear opalescence, posterior
subcapsular opacity, or changes in nuclear color) according
to the Lens Opacity Classification System III (LOCS III) [19];
had any corneal, retinal, or orbital diseases; presented with
an absolute spherical refractive error >5D or an absolute
cylindrical error>3D; orwere using alpha-adrenergic agonist
eye drop medication or any systemic medication that might
affect PLR. Participants with a history of taking psychoactive
agents were excluded from the study. In addition, none of
our patients reported any travel or shift work during the
examination period. Only patients with an open angle at
gonioscopy were included in our study.
The participants were considered as having glaucoma if
they had at least 3 repeatable, consecutive, abnormal visual
field test results, which were defined as a pattern standard
deviation outside the 95% confidence interval for the normal
range or a glaucoma hemifield test result outside the normal
limits and a corresponding alteration in the appearance of the
optic disc. Patients were also considered as having glaucoma
if they showed signs of glaucomatous optic neuropathy at
clinical examination by a glaucoma expert, confirmed by
stereophotography. Glaucomatous damage to the optic disc
nerve was defined as the presence of RNFL defects or
localized or diffuse neuroretinal rim loss.
The control participants showed normal results at oph-
thalmological examination, an IOP of <21mmHg, normal
visual field test results, and absence of glaucomatous optic
neuropathy based on fundoscopic and stereoscopic optic disc
photograph evaluations.
The entire cohort (i.e., the 30 patients with primary
open-angle glaucoma and the 10 controls) belongs to the
same sample of a study that was published elsewhere [15, 17].
No additional participant was recruited to augment that
previously published sample [15, 17].
2.2. Sleep Disorder Questionnaire. Sleep disorders were eval-
uated using the ESS, which has been widely used as a
subjective measurement of daytime sleepiness [18]. This test
measures the probability of falling asleep across eight daily
situations; each question is scored as 0 (e.g., would never
doze), 1 (slight change of dozing), 2 (moderate chance of
dozing), or 3 (high chance of dozing), for a total possible
score of 24. The clinically normal score of this scale ranges
from 2 to 10. A score higher than 10 indicates a borderline or
increased level of chronic sleepiness, and a score higher than
15 is defined as excessive daytime sleepiness [18].
2.3. PLR Test. Measurement of the PLR was based on a
method developed by Park et al. [20]; our previous studies
[15, 17] and other research groups have used this technique
[21]. To preferentially stimulate ipRGC function, we used
470 nm (blue) flashes with luminance of 250 cd/m2 (14.1 log
photons/cm2/s melanopic excitation) [2] of 1 s in duration.
Alternatively, to preferentially stimulate different retinal pho-
toreceptors (e.g., cones and rods) without directly stimulating
the ipRGCs, we used 640 nm (red) flashes of 1 s in dura-
tion with luminance of 250 cd/m2 (10.7 log photons/cm2/s
melanopic excitation) [2]. Table 1 summarizes full equations
for calculating illuminance values for ipRGC, cones, and rods
functions [2]. For each stimulus, a red flash was presented
first, followed by a blue flash 60 s after the offset of the red
flash. The interval between stimuli was used to allow the
pupil size to return to baseline before the presentation of
the subsequent stimulus. Both eyes were tested monocularly
in a random order. One pupillometric measurement per
participant was performed. The patients were dark-adapted
for 10min; then, alternating 1 s red and blue flashes were
presented at luminance of 250 cd/m2 (10.7 and 14.1 log
photons/cm2/s melanopic excitation, resp.) [2].
Stimuli were generated by corresponding light-emitting
diodes (LEDs) in a Ganzfeld system (RETIport; Roland Con-
sult, Brandenburg, Germany), and responses were recorded
using an eye-tracking camera system with an infrared LED
(IR333-A; Arrington Research, Scottsdale, AZ, USA). The
Arrington Research infrared camera recorded the procedure
at 60 frames per second.The peak wavelength of the infrared
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Table 1: Photometric measures for different photoreceptors’ inputs to circadian and neurophysiological light responses in humans [2].
Photoreceptor Photopigment Spectral sensitivity function Unit of measurea
Short-wavelength (S) cones S-cone photopsin(cyanolabe) Cyanolabe response function𝑁sc (𝜆)
Cyanopic illuminance
(cyanopic-lux)
Medium-wavelength (M) cones M-cone photopsin(chlorolabe) Chlorolabe response function𝑁mc (𝜆)
Chlorolabe illuminance
(chloropic-lux)
Long-wavelength (L) cones L-cone photopsin(erythrolabe) Erythrolabe response function𝑁lc (𝜆)
Erythrolabe illuminance
(erythropic-lux)
ipRGCs (intrinsic
photosensitivity) Melanopsin Melanopsin response function𝑁𝑧 (𝜆)
Melanopsin illuminance
(melanopic-lux)
Rods Rod opsin Rod opsin response function𝑁
𝑟
(𝜆) Rhodopic illuminance(rhodopic-lux)
a = each unit ofmeasure (Ea, where a specifies the retinal photopigment) is derived by convoluting the spectral power distribution of incident light (Eel) with the
relevant spectral sensitivity function, which in turn is defined by the photopigment spectral sensitivity adjusted for prereceptoral filtering in a standard observer
(Na(l); see the online reference (http://www.cie.co.at/index.php?i ca id=983) [28] for full functions and a detailed description of their derivation) according
to the equation Ea = 72 983.25 R Eel(l) Na(l) dl. Species-specific variants of the spectral sensitivity functions may be required for nonhuman applications to
account for differences in prereceptoral filtering and photopigment spectral sensitivity [2].
LEDs was 940 nm [20, 22, 23]. Pupil size was directly
measured; the largest diameter was considered as the primary
measure. The peak PLR amplitude was calculated as the
maximal pupillary constriction and expressed relative to the
baseline value (peak PLR amplitude = maximal constriction
diameter/baseline diameter) [20]. In addition, the sustained
PLR was expressed as the pupil diameter 6 s after the flash
offset relative to baseline [20].The absolute values of the peak
and sustained responses to blue and red flashes at 250 cd/m2
for a similar cohort were reported in our previous studies
[15, 17].
2.4. Polysomnography. To obtain sleep parameter data, poly-
somnographic recordings were performed over a full night
in a temperature-controlled and sound-attenuated room
(EMBLA S7000, Embla Systems Inc., Broomfield, CO, USA).
Thedetails of thismethodology have been described and used
previously elsewhere [17].
The following parameters were included in the poly-
somnographic assessment [24]: total sleep time (TST; the
amount of actual sleep time over a sleep period); sleep
efficiency (TST per sleep period); sleep latency (i.e., the
amount of time before starting the effective sleep period);
REM sleep latency (i.e., the amount of time before starting
REM sleep); and the S1 to S3 and REM sleep stages (as a
percentage of TST) [25]. Arousal was defined as a ≥ 3 s
increase in the electroencephalographic frequency preceded
by ≥10 s of stable sleep [25].The following data were collected
for the arousal assessment: total arousal duration after falling
asleep (in minutes), total number of arousals (𝑛), and arousal
index (number of events per hour) [25].The apnea-hypopnea
index (AHI, event count per hour of TST) was calculated
as the total number of episodes of apnea and hypopnea
per hour of electroencephalographically confirmed sleep.
Apnea was defined as the cessation of airflow for at least 10 s
combined with the effort to breathe. Hypopnea was classified
as a minimum 30% reduction in thoracoabdominal move-
ment or airflow compared with baseline lasting at least 10 s
together with ≥4% oxygen desaturation [26]. Our previous
study reported different polysomnographic parameters from
a similar cohort [15, 17].
A board-certified physicianwhowas unaware of the study
design (andwas therefore blind to patients’ ophthalmic exam-
ination results) analyzed the polysomnographic tests. The
polysomnographic tests were performed within 6 months of
the administration of the ESS questionnaire, the ophthalmo-
logical exams, and the PLR tests.Theophthalmological exams
and the PLR tests were performed within a 1-month interval.
2.5. Statistical Analyses. Both eyes of each participant were
included in this analysis. To correct for the bias introduced
by the expected correlation between the two eyes of each
participant, a generalized estimating equation (GEE) was
used to adjust for intereye correlations [27]. After adjusting
for within-patient intereye correlations, the GEE was used to
examine the relationship between the ESS score and the PLR
across the entire cohort. In addition, a linear regression was
used to determine the association between the ESS score and
the polysomnographic parameters for both groups [27].
To obtain the correlation coefficients regarding the asso-
ciation between the ESS score and the PLR as well as
the polysomnographic parameters, a linear regression was
performed. Whenever both eyes were eligible, the right eye
was arbitrarily selected for this specific analysis. Participant
age was examined as a covariate.
Statistical analyses were performed using commercially
available Stata software (version 13, StataCorp LP, College
Station, TX, USA). The 𝛼 level (type I error) was set at 0.05.
3. Results
This study examined both eyes of 40 subjects: 30 with glau-
coma and 10 healthy (control group). The mean (±standard
deviation) ages of the control and glaucoma groups were
56.10 ± 8.08 (range = 45 to 74) and 62.00 ± 9.39 (range = 42
to 75) years, respectively (𝑝 = 0.084). The demographic and
clinical characteristics of the participants are summarized in
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Table 2: Demographic and clinical characteristics (mean ± standard deviation [median, interquartile range]) of control and glaucoma
participants.
Control group (𝑁 = 20 eyes of 10
subjects)
Glaucoma group (𝑁 = 60 eyes of 30
subjects) 𝑝 value
Age, years 56.10 ± 8.08(55.50, 54.00 to 58.00)
62.00 ± 9.39
(64.50, 53.00 to 70.00) 0.084
a
Female, % 8 (80%) 20 (67%) 0.693c
Ancestry, % 0.401c
Caucasian 9 (90%) 21 (70%)
African-American 1 (10%) 9 (30%)
MD worse eye, dB −1.28 ± 2.03(−1.23, −3.10 to 0.44)
−11.82 ± 10.68
(−7.15, −20.22 to −3.07) <0.001
b
MD better eye, dB −0.04 ± 1.60 (0.27, −1.18 to 1.52) −7.00 ± 7.97 (−2.90, −11.78 to −1.34) <0.001b
Average IOP, mmHg 13.42 ± 1.87 (13.00, 12.00 to 14.00) 16.90 ± 2.82 (16.00, 15.00 to 18.00) <0.001b
Cup/disc ratio 0.34 ± 0.10 (0.30, 0.30 to 0.40) 0.80 ± 0.15 (0.80, 0.70 to 1.00) <0.001b
CCT, 𝜇m 539.95 ± 30.24(534.00, 519.00 to 562.00)
521.76 ± 34.52 (520.50, 498.00 to
547.00) 0.069
a
Visual acuity,
logMAR 0.04 ± 0.07 (0.00, 0.00 to 0.10) 0.11 ± 0.09 (0.10, 0.00 to 0.20) <0.001
a
MD =mean deviation; dB = decibels; IOP = intraocular pressure; mmHg = millimeters of mercury; CCT = central corneal thickness; logMAR = logarithm of
the minimum angle of resolution.
aStudent’s 𝑡-test; bWilcoxon’s rank-sum test; cFisher’s exact test.
Significant values are in boldface.
Table 2. Relevant variation was present with regard to the
average MD in the glaucomatous eyes, ranging from −32.28
to 0.53 dB.
3.1. Overall ESS Results. Themean ESS score of the glaucoma
patients was significantly higher than that of the control
group (13.10 ± 5.14 and 9.10 ± 3.73, resp., 𝑝 = 0.029). With
regard to sample size, nineteen glaucoma patients (63.33%)
and three control patients (30.00%) reported an ESS score
>10, which is considered as borderline or indicative of an
increased level of chronic sleepiness; however, this difference
was not significant (𝑝 = 0.234; Fisher’s exact test). The ESS
score was greater than 15 for 10 of the participants in the
glaucoma group (33.33%), suggesting a high level of daytime
sleepiness; however, none of the participants in the control
group had an ESS score greater than 15. Figure 1 illustrates
the distribution of the ESS scores among the controls and
glaucoma patients.
A significant associationwas found between the ESS score
and glaucoma severity based on SAP MD (𝑝 < 0.001);
specifically, higher ESS scores were related to worse damage
(Figure 2(a)).
3.2. Association between Polysomnography and ESS Results.
Table 3 shows the associations between the ESS scores and
the polysomnographic parameters for the entire cohort. A
significant inverse correlation was observed between the
ESS score and sleep efficiency (𝑝 = 0.002), indicating
that higher ESS scores were associated with lower sleep
efficiencies. A significant association was also found between
the ESS score and arousal duration after falling asleep (𝑝 <
0.001); specifically, higher ESS scores were related to longer
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Figure 1: Boxplot depicting the distribution of the ESS scores in the
control and glaucoma groups. Box: median and interquartile range
(IQR). The whiskers show the maximal and minimal 1.5 IQR.
arousal durations after falling asleep. The ESS score was also
associated with the number of arousals and the arousal index
(𝑝 = 0.039 and 𝑝 = 0.013, resp.). Figure 2(b) illustrates the
association between the ESS score and the number of arousals
at polysomnography for the entire cohort. Age was included
in the multivariate model but did not exert a significant effect
(𝑝 > 0.05 for all polysomnographic parameters).
3.3. Association between PLR Test and ESS Results. A signifi-
cant inverse correlation was observed between the ESS score
and the peak response to the blue flash with a luminance
of 250 cd/m2 (𝑝 = 0.017, 𝑅2 = 0.080). Furthermore, a
significant correlation was found between the ESS score and
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Figure 2: Scatterplot depicting the negative association (a) between the SAP MD and the ESS scores, the positive association between the
arousal parameters at polysomnography and the ESS scores (b), and the negative relationship between the sustained pupillary response to the
blue flash at 250 cd/m2 and the ESS score (c) in the control and glaucoma groups. The shaded area represents the prediction interval of the
regression.
Table 3: Associations (𝑅2) between the polysomnographic param-
eters and the ESS scores∗.
Parameter 𝑝 value 𝑅2
Arousal duration after falling asleep (min) <0.001 0.252
Sleep efficiency (%) 0.002 0.214
Arousals (𝑛) 0.039 0.163
Arousal index (𝑛/h) 0.013 0.133
TST (min) 0.050 0.159
Sleep latency (min) 0.592 0.120
REM sleep latency (min) 0.667 0.119
Sleep stage (%)
S1 0.848 0.118
S2 0.057 0.157
S3 0.150 0.140
REM 0.782 0.118
∗Linear regression model including the polysomnographic parameters and
the ESS scores.
Significant values are in boldface.
the sustained response to the blue flash with luminance of
250 cd/m2 (𝑝 = 0.009, 𝑅2 = 0.068). A higher ESS score
was associated with lower peak and sustained responses to
the blue flash at 250 cd/m2. Figure 2(c) shows the association
between the ESS score and the sustained response to the blue
flash with luminance of 250 cd/m2 for the entire cohort.
An inverse association was also found between the ESS
score and the sustained response to the red flash at 250 cd/m2
(10.7 log photons/cm2/s2) (𝑝 = 0.010; 𝑅2 = 0.080); specifi-
cally, a higher ESS score was associated with a lower sustained
response to the red flash with luminance of 250 cd/m2 (10.7
log photons/cm2/s). However, no correlation was observed
between the ESS score and the peak response to the red flash
at 250 cd/m2 (10.7 log photons/cm2/s; 𝑝 = 0.199; 𝑅2 = 0.021).
In addition, age was examined in the multivariate model;
however, it was found not to exert a significant effect on
the associations between the ESS score and either the peak
or sustained response to the blue flash with luminance
of 250 cd/m2 for either the control or glaucoma group
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(𝑝 = 0.403 and 𝑝 = 0.290, resp.). In addition, age did not
significantly affect the associations between the ESS score and
either the peak or sustained response to the red flash with
luminance of 250 cd/m2 for either the control or glaucoma
group (𝑝 = 0.223 and 𝑝 = 0.375, resp.).
4. Discussion
This study used the ESS to evaluate sleep disorders, specif-
ically daytime sleepiness, in glaucoma patients. In addition,
we addressed the relationship between the ESS score and both
polysomnographic measures and PLR in glaucoma patients.
Increased daytime sleepiness, as measured by the ESS, was
associated with arousal duration after falling asleep, sleep
efficiency, number of arousals, and the arousal index at
polysomnography. In addition, increased ESS scores were
associated with reduced peak and sustained PLRs to a blue
flash with luminance of 250 cd/m2. To the best of our
knowledge, this study is the first to identify the associa-
tions between daytime sleepiness and polysomnography and
PLR parameters. Sleep disorders (evaluated using ESS and
polysomnography) and PLRmight be related to certain types
of ipRGCs [29].
The results of this study are in agreement with those of
previous studies showing that glaucoma is associated with a
decrease in sleep quality [16, 30, 31].Wang et al. used the PSQI
to investigate whether glaucoma affects sleep quality and to
evaluate the differences between disparate types of glaucoma
(i.e., primary open-angle glaucoma and primary closed-angle
glaucoma) [16]. These authors found that the prevalence of
sleep disorderswas higher among patientswith glaucoma and
that the patients with primary closed-angle glaucoma had a
greater incidence of sleep disorders than those with primary
open-angle glaucoma [16]. Using the ESS, we demonstrated
that patientswith glaucoma showed increased daytime sleepi-
ness. The ESS is a self-report questionnaire that is considered
as the gold standard for assessing daytime sleepiness [18];
however, to date, the ESS score has never been used to
investigate glaucoma patients. We hypothesized that ocular
damage in patients with glaucoma affects all types of RGCs
(including ipRGCs) and that this damage is linked to the
dysregulation of the circadian system, thereby leading to
decreased sleep quality and resulting in excessive daytime
sleepiness.
The finding in our study supported these hypotheses,
showing that patients with glaucoma have higher daytime
sleepiness associated with worse parameters in polysomnog-
raphy. The excessive daytime sleepiness observed among
glaucoma patients was likely because of the increased number
or total duration of arousals after falling asleep, decreased
sleep efficiency, and briefer TST. Daytime sleepiness (as
measured using the ESS) was also associated with differ-
ent polysomnographic parameters such as sleep efficiency,
arousal duration after falling asleep, arousals, and the arousal
index. A previous study performed by our group demon-
strated that patients with glaucoma have significantly lower
average TSTs and sleep efficiencies as well as longer arousal
durations after falling asleep [17].
Daytime sleepiness was also associated with PLR, a well-
known indicator of the afferent input from the retina and
the optic nerve. Most optic neuropathies show an association
between PLR and disease severity [32–36]. Briefly, the PLR
shows a transient phase of pupillary constriction, which is
attributed to rod and cone input to the ipRGCs, followed
by sustained pupil constriction, which is primarily driven by
the melanopsin response in the ipRGCs [20, 37]. Previous
studies have shown an inverse correlation between sustained
pupillary constriction and glaucoma severity [11, 13, 15].
For example, Gracitelli et al. showed that the sustained
response to the blue flash at 250 cd/m2 (which preferentially
stimulates ipRGCs [3, 4]) was reduced in patients with
advanced glaucoma (i.e., patients with SAP MD worse than
−12 dB) [15]. In addition, a thinner RNFL was associated
with a reduced sustained pupillary response [15].The present
study adds new information by showing that, in addition
to the decreased sustained pupillary response in glaucoma
patients, the degree of daytime sleepiness is associated with
a reduced sustained response to a blue flash at 250 cd/m2.
One possible explanation for this finding is that ipRGCs
are among the cells in the total RGC population that are
damaged in glaucoma patients; thus, they affect several func-
tions of ipRGCs, including the PLR and circadian rhythms.
Importantly, although a significant association was observed
between daytime sleepiness and the PLR in this study,
the correlation coefficient was not substantial (𝑅2 = 0.080
for the correlation between the ESS score and peak PLR
and 𝑅2 = 0.068 for the correlation between the ESS score
and the sustained PLR). Thus, important, unknown factors
most likely contribute to this correlation. For example, the
subjectivity of all self-report questionnaires might affect the
final score. In addition, studies performed by Pack et al. and
Gooneratne et al. showed that self-reported questionnaire of
sleepiness can often be inaccurate when viewed alongside
quantitative measures of alertness and sometimes is often
viewed as a common and natural aspect of aging that can lead
to a misinterpretation of the results [38, 39].
In addition, daytime sleepiness, in glaucoma group, was
associated with a sustained PLR to the red flash. The peak
and sustained PLRs to a red flash are well known to be
correlated with the number and function of the rods and
cones, not ipRGCs. One hypothesis explaining this finding
is that rod and cones photoreceptors might also be affected
in patients with chronic or advanced glaucoma, resulting in
decreased signaling from these cells [40–42]. However, this
topic remains controversial in the literature [40–43], and
additional studies must be conducted to clarify the actual
connection between the functions of ipRGCs and rod and
cones photoreceptors.
Another interesting issue is the controversy concerning
the relative preservation of ipRGCs among the diversity of
RGCs [21, 44–47]. Li et al. showed that although the con-
ventional RGC number was decreased in rats with increased
IOP, the number of ipRGCs did not change. This result
suggests that ipRGCs were resistant to the deleterious effects
caused by increased IOP [45].However, another study inmice
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demonstrated that ipRGCs appeared to be resistant to damage
resulting from IOP elevation at an early age (approximately 5
months) but became vulnerable at a later age (approximately
11 months) [48]. The authors of that study suggested that
the magnitude of IOP elevation required to damage ipRGCs
must be greater than that required to induce RGC damage
[48, 49]. In addition, Drouyer et al. and de Zaval´ıa et al.
showed that glaucomatous rats and other rodents exhibited a
delayed phase angle with respect to darkness [46, 47]. These
results are in agreement with ours, suggesting that glaucoma
induces a circadian system dysfunction. One explanation for
the differences between certain animal models and studies
of patients with glaucoma is the endpoint evaluated, that is,
morphological versusfunctional endpoints [49].The primary
focus of human studies has typically been ipRGC function,
whereas the number and morphology of these cells have
usually been considered in animal studies. The resistance
mechanism that underlies the survival of ipRGCs is currently
unknown. Although this question persists, our study ana-
lyzed two different functions involving ipRGCs in the same
group of patients, and we found a strong association between
them.Thus, our results strongly suggest that both non-image-
forming functions of ipRGCs were affected.
Recently, Chen et al. demonstrated that there is not one
specific type of ipRGC; rather, different subpopulations of
ipRGCs exist with similar properties that innervate disparate
brain regions to execute specific functions, such as the PLR
and circadian photoentrainment [50]. In this study, pupil
constriction, circadian oscillation (wheel running activity),
the adjustment of the circadian clock to different light stimuli
(i.e., circadian photoentrainment, “jet-lag” paradigms, phase
shifting, and skeleton photoperiod), and the direct effect
of constant and ultradian light on activity were measured
[50]. The results showed that ipRGCs comprise functionally
distinct subpopulations that differentially express a specific
transcription factor [50]. ipRGCs that do not express this
transcription factor innervate the suprachiasmatic nucleus
of the hypothalamus, whereas ipRGCs that express this
transcription factor innervate other known brain targets such
as the olivary pretectal nucleus.Thus, the ipRGCs that express
this transcription factor are associated with the PLR but not
with circadian photoentrainment [50]. Because we did not
evaluate this issue in the present study, future investigations
should be conducted to elucidate the subpopulations of
ipRGCs to determine how they are involved in non-image-
forming functions.
The primary clinical finding of this study was that glau-
coma patients had increased daytime sleepiness compared
with healthy participants, and these results were associated
with worse polysomnographic parameters and lower sus-
tained PLRs to a blue flash with luminance of 250 cd/m2.
Therefore, circadian rhythm regulation, which is linked with
ipRGCs’ functions, should be evaluated in certain patients
with glaucoma. Excessive daytime sleepiness is well known
to affect quality of life, daytime function, and mortality;
furthermore, previous studies of geriatric populations have
revealed that excessive daytime sleepiness is associated with
age, disability, dementia, and vision and hearing impairments
[51].
This study has limitations. First, a relatively small number
of patients were included in this study. Although future stud-
ies with greater numbers of patients should be undertaken
to better understand the role of ipRGCs in sleep disorders,
the present study did show strong agreement between the
subjective and objective measures of sleep quality among
patients with glaucoma. Second, sleep patterns are most
likely affected by factors other than the hypothesized ipRGC
loss associated with glaucoma. However, the subjective and
objectivemeasures of sleep quality (i.e., the ESS questionnaire
and the polysomnographic parameters) strongly suggested
that the damage to ipRGCs associated with glaucoma results
in certain types of sleep disorders. Furthermore, regarding
the primary endpoint of this study, we relied on self-reported
histories of daytime sleepiness; it is possible that inaccuracies
were present in patient recollection and reporting. However,
we also used polysomnographic parameters (i.e., the gold
standard test of sleep quality), and these parameters were in
agreement with the ESS scores. In addition, because patient
age is associated with a decrease in sleep quality and can
affect PLR, this variable might have affected our final results
[16, 51]. Although the influence of age-related factors could
not be completely excluded, our study did not reveal any
significant differences in age between the two groups, and
the multivariate analysis found that age was not a significant
covariate. In addition, previous studies have shown that the
postillumination response did not significantly decrease with
age [52] and that only pupil diameter was reduced among the
elderly population [52].
In conclusion, the results of this study demonstrated
that patients with glaucoma had increased daytime sleepi-
ness relative to healthy controls as measured by a self-
report questionnaire. In addition, daytime sleepiness was
associated with a reduced sustained pupillary response
and polysomnographic parameters. These ipRGC functions
might be impaired in patients with glaucoma, thereby affect-
ing their quality of life.
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